WO2010052466A3 - Pharmaceutical aerosol composition - Google Patents

Pharmaceutical aerosol composition Download PDF

Info

Publication number
WO2010052466A3
WO2010052466A3 PCT/GB2009/002617 GB2009002617W WO2010052466A3 WO 2010052466 A3 WO2010052466 A3 WO 2010052466A3 GB 2009002617 W GB2009002617 W GB 2009002617W WO 2010052466 A3 WO2010052466 A3 WO 2010052466A3
Authority
WO
WIPO (PCT)
Prior art keywords
aerosol composition
pharmaceutical aerosol
pharmaceutical
adjuvant
optionally
Prior art date
Application number
PCT/GB2009/002617
Other languages
French (fr)
Other versions
WO2010052466A8 (en
WO2010052466A2 (en
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Limited
Curtis, Philip, Anthony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/002575 external-priority patent/WO2010052450A1/en
Priority to AU2009312598A priority Critical patent/AU2009312598A1/en
Priority to NZ592861A priority patent/NZ592861A/en
Priority to MX2011004730A priority patent/MX2011004730A/en
Priority to CN200980148430.5A priority patent/CN102238939B/en
Priority to UAA201107033A priority patent/UA106215C2/en
Priority to BRPI0916047A priority patent/BRPI0916047A2/en
Priority to EP09753178A priority patent/EP2362766A2/en
Application filed by Cipla Limited, Curtis, Philip, Anthony filed Critical Cipla Limited
Priority to RU2011122652/15A priority patent/RU2565438C2/en
Priority to JP2011535158A priority patent/JP2012507574A/en
Priority to CA2742718A priority patent/CA2742718A1/en
Publication of WO2010052466A2 publication Critical patent/WO2010052466A2/en
Publication of WO2010052466A3 publication Critical patent/WO2010052466A3/en
Publication of WO2010052466A8 publication Critical patent/WO2010052466A8/en
Priority to US13/685,949 priority patent/US20130160761A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

A pharmaceutical aerosol composition comprising at least one hydrofluoroalkane propellant; at least one active agent complexed with an adjuvant; and, optionally, at least one pharmaceutically acceptable excipient.
PCT/GB2009/002617 2008-11-04 2009-11-04 Pharmaceutical aerosol composition WO2010052466A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2742718A CA2742718A1 (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition
EP09753178A EP2362766A2 (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition
MX2011004730A MX2011004730A (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition.
CN200980148430.5A CN102238939B (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition
UAA201107033A UA106215C2 (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition
BRPI0916047A BRPI0916047A2 (en) 2008-11-04 2009-11-04 aerosol pharmaceutical composition, use of an aerosol pharmaceutical composition, method for treating severe, moderate or mild acute or chronic symptoms, or for prophylactic treatment of a respiratory disorder, aerosol pharmaceutical dispenser, process for manufacturing an aerosol pharmaceutical dispenser and process for making a complex of an active agent and an adjuvant
RU2011122652/15A RU2565438C2 (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition
AU2009312598A AU2009312598A1 (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition
NZ592861A NZ592861A (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition
JP2011535158A JP2012507574A (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition
US13/685,949 US20130160761A1 (en) 2008-11-04 2012-11-27 Pharmaceutical Aerosol Composition

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN2351MU2008 2008-11-04
IN2351/MUM/2008 2008-11-04
IN2402/MUM/2008 2008-11-14
IN2402MU2008 2008-11-14
GBPCT/GB2009/002575 2009-10-29
PCT/GB2009/002575 WO2010052450A1 (en) 2008-11-04 2009-10-29 Tiotropium bromide having a low degree of crystallinity

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13127656 A-371-Of-International 2009-11-04
US13/685,949 Continuation US20130160761A1 (en) 2008-11-04 2012-11-27 Pharmaceutical Aerosol Composition

Publications (3)

Publication Number Publication Date
WO2010052466A2 WO2010052466A2 (en) 2010-05-14
WO2010052466A3 true WO2010052466A3 (en) 2010-11-04
WO2010052466A8 WO2010052466A8 (en) 2011-11-24

Family

ID=41630445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002617 WO2010052466A2 (en) 2008-11-04 2009-11-04 Pharmaceutical aerosol composition

Country Status (12)

Country Link
EP (1) EP2362766A2 (en)
JP (1) JP2012507574A (en)
KR (1) KR20110096538A (en)
CN (1) CN102238939B (en)
AU (1) AU2009312598A1 (en)
BR (1) BRPI0916047A2 (en)
CA (1) CA2742718A1 (en)
MX (1) MX2011004730A (en)
NZ (1) NZ592861A (en)
RU (1) RU2565438C2 (en)
WO (1) WO2010052466A2 (en)
ZA (1) ZA201103347B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2493827C1 (en) * 2012-10-03 2013-09-27 Шолекс Девелопмент Гмбх Stable combined solution of fenoterol hydrobromide and ipratropium bromide
KR20150096371A (en) * 2012-10-23 2015-08-24 시플라 리미티드 Pharmaceutical composition
GB201306984D0 (en) * 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
KR101484481B1 (en) * 2014-08-07 2015-01-20 주식회사 다림바이오텍 Manufacturing method of subligual spray composition comprising PDE-5 inhibitor, and subligual spray composition manufactured by the same
CN107320464A (en) * 2017-04-28 2017-11-07 北京北朋科技有限公司 The preparation method of the budesonide suspension of high pH value
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2020070620A2 (en) * 2018-10-01 2020-04-09 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
CN114796166A (en) * 2021-01-29 2022-07-29 北京远大九和药业有限公司 Aerosol containing terpene volatile oil and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641800B1 (en) * 1991-09-25 2003-11-04 Fisons Ltd. Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684698A (en) * 1986-05-02 1987-08-04 Gaf Corporation Water soluble multicomplex of chlorothiazide, furosemide and poly(N-vinyl-2-pyrrolidone)
EP0655237A1 (en) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medicinal aerosol formulation
US6361760B1 (en) * 1995-09-19 2002-03-26 Fujisawa Pharmaceutical Co., Ltd. Aerosol compositions
EP1019021B2 (en) * 1997-09-29 2012-12-26 Novartis AG Stabilized preparations for use in metered dose inhalers
DE10214031A1 (en) * 2002-03-27 2004-02-19 Pharmatech Gmbh Process for the production and application of micro- and nanoparticles by micronization
SI1682542T1 (en) * 2003-11-03 2010-04-30 Boehringer Ingelheim Int Novel crystalline anhydride with anticholinergic effect
SI1881980T1 (en) * 2005-05-02 2012-12-31 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
ES2384486T3 (en) * 2005-12-19 2012-07-05 Sicor, Inc. New form of tiotropium bromide and procedure for its preparation
EP2327403A3 (en) * 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641800B1 (en) * 1991-09-25 2003-11-04 Fisons Ltd. Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane

Also Published As

Publication number Publication date
AU2009312598A1 (en) 2010-05-14
ZA201103347B (en) 2012-01-25
BRPI0916047A2 (en) 2015-11-10
NZ592861A (en) 2013-01-25
CA2742718A1 (en) 2010-05-14
RU2011122652A (en) 2012-12-20
RU2565438C2 (en) 2015-10-20
JP2012507574A (en) 2012-03-29
KR20110096538A (en) 2011-08-30
EP2362766A2 (en) 2011-09-07
MX2011004730A (en) 2011-05-30
WO2010052466A8 (en) 2011-11-24
CN102238939B (en) 2015-05-20
CN102238939A (en) 2011-11-09
WO2010052466A2 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
WO2010052466A8 (en) Pharmaceutical aerosol composition
WO2006101882A3 (en) Medicament delivery formulations, devices and methods
WO2007135193A3 (en) Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
WO2007079448A3 (en) Three component carbohydrate vaccine
WO2008120207A3 (en) Compositions for nasal delivery
WO2009062746A3 (en) Topical drugs for use in antifungal therapy
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP1998751A4 (en) Devices, systems and methods for medicament delivery
WO2012085657A3 (en) Tamper resistant solid oral dosage forms
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
ZA200704163B (en) Oral medicament for the modified release of at least one active principle, in a multimicrocapsule form
WO2007144169A3 (en) Entacapone-derivatives
WO2006127941A3 (en) Amorphous cinacalcet hydrochloride and preparation thereof
WO2008152398A3 (en) Formulations for inhalation
WO2011120904A3 (en) A fast dissolving pharmaceutical composition
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
WO2011076212A3 (en) Processes for the manufacture of a pharmaceutically active agent
WO2010021607A3 (en) Pharmaceutical formulation
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
WO2009149058A8 (en) Modified release niacin formulations
WO2008003050A3 (en) Gallium nitrate formulations
EP2316420A8 (en) Method to reduce pain
WO2011120903A3 (en) A fast dissolving pharmaceutical composition
WO2011058336A3 (en) Tablet comprising gum arabic
WO2008036808A3 (en) Pesticide formulation with streaming birefringence

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980148430.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09753178

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2742718

Country of ref document: CA

Ref document number: 2011535158

Country of ref document: JP

Ref document number: MX/A/2011/004730

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 923/MUMNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 592861

Country of ref document: NZ

Ref document number: 2009312598

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2009753178

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009753178

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117012589

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009312598

Country of ref document: AU

Date of ref document: 20091104

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201107033

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 2011122652

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0916047

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110504